Episode Details
Back to Episodes
Jefferies London: Zealand Pharma CEO Adam Steensberg believes that amylins will overtake GLPs as the backbones of obesity treatments in the future
Published 9 months, 4 weeks ago
Description
He discusses Zealand's partnership with Roche, and new data that will be coming next year. Plus, the company's partnership with Boehringer on survodutide.